Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jphs.2019.09.014 http://scihub22266oqcxt.onion/10.1016/j.jphs.2019.09.014 31924408!?!31924408 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=31924408&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Pharmacol+Sci 2020 ; 142 (3): 124-126 Nephropedia Template TP {{tp|p=31924408|t=2020. The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats |pdf=|usr=}}{{31924408}} gab.com Text The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats JO: J Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=31924408 #FOAvip We examined the effects of the angiotensin receptor-neprilysin inhibitor LCZ696 on overt proteinuria and renal injury in type 2 diabetic Otsuka-Long- Evans-Tokushima-Fatty (OLETF) rats. Aged OLETF rats were also treated with either valsartan or valsartan plus hydralazine for comparison. LCZ696 caused greater attenuation of the progression of proteinuria than either valsartan alone or valsartan combined with hydralazine. Reduced glomerular injury and tubulointerstitial fibrosis were also observed in LCZ696-treated rats. Moreover, LCZ696 prevented increases in blood urea nitrogen (BUN) and creatinine levels. These data suggest that LCZ696 elicits a reno-protective effect against type 2 diabetes with overt proteinuria. Twit Text FOAVip The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats ????J Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=31924408 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=31924408 #FOAvip English Wikipedia <ref>{{Cite pmid|31924408}}</ref> The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats #MMPMID31924408 Rahman A; Sherajee SJ; Rafiq K; Kobara H; Masaki T; Nakano D; Morikawa T; Konishi Y; Imanishi M; Nishiyama A J Pharmacol Sci 2020[Mar]; 142 (3): 124-126 PMID31924408show ga We examined the effects of the angiotensin receptor-neprilysin inhibitor LCZ696 on overt proteinuria and renal injury in type 2 diabetic Otsuka-Long- Evans-Tokushima-Fatty (OLETF) rats. Aged OLETF rats were also treated with either valsartan or valsartan plus hydralazine for comparison. LCZ696 caused greater attenuation of the progression of proteinuria than either valsartan alone or valsartan combined with hydralazine. Reduced glomerular injury and tubulointerstitial fibrosis were also observed in LCZ696-treated rats. Moreover, LCZ696 prevented increases in blood urea nitrogen (BUN) and creatinine levels. These data suggest that LCZ696 elicits a reno-protective effect against type 2 diabetes with overt proteinuria. |Aminobutyrates/*therapeutic use[MESH] |Angiotensin Receptor Antagonists/*therapeutic use[MESH] |Animals[MESH] |Biphenyl Compounds[MESH] |Diabetes Mellitus, Type 2/*complications[MESH] |Drug Combinations[MESH] |Proteinuria/*drug therapy/*etiology[MESH] |Rats[MESH] |Rats, Inbred OLETF[MESH] |Tetrazoles/*therapeutic use[MESH]The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the(epmc).pdf DeepDyve Pubget Overpricing